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With one third of the Hepatitis B virus (HBV) infection population of the world, chronic 
Hepatitis B (CHB) has become a top burden in China. CHB is a lifelong infection with HBV 
which can cause serious health problems, like cirrhosis, liver cancer or even death. HBV 
infection is known to result in various clinical conditions, including asymptomatic HBV 
carriers to chronic hepatitis and primary hepatocellular carcinoma. Several studies have 
shown that host genetic susceptibility could be an important factor that determines these 
various outcomes of HBV infection. Many Single Nucleotide Polymorphisms (SNPs) and 
Copy Number Variations (CNVs) have been associated with genetic susceptibility for 
many diseases including the HBV infection. SNPs and CNVs of the host could determine 
the CHB outcomes and disease progression. In this project, we conducted SNP-based 
and copy number polymorphic region (CNPR) - based CNV analysis of the genotyping 
data generated from 2,689 CHB patients and 1,200 healthy controls in Chinese 
population by Illumina Human OmniExpress BeadChip and OmniZhonghua BeadChip.  
Based on the analysis results, we found 8 deletion CNPRs, as well as 3 duplication 
CNPRs were significantly changed between CHB patients and healthy controls. Moreover, 
there were nine genes revealed the copy number loss, including FGFR3 (p=1.49X10-7), 
FGR-3 (p=1.49X10-7), LETM1 (p=1.49X10-7), TACC3 (p=1.49X10-7), TMEM129 
(p=1.49X10-7), PANK4 (p=4.55X10-4), PLCH2 (p=4.55X10-4), CED-6 (p=2.04X10-4), 
DIRC1 (p=2.04X10-4), as well as three genes revealed the copy number gain, including 
FLJ43080 (p=2.50X10-5), CSMD3 (p=6.288X10-5), MGAT4C (p=1.52X10-4) in CHB 
patients compared with healthy controls. It is important to understand the functions of 
these genes and the mechanisms through which these genes are associated with HBV 
infection and CHB development. Through the CNVs analysis, we provided potential 
therapeutic targets and novel diagnosis markers for HBV infection and CHB development.   
 
Introduction 
Southern Medical University Nanfang Hospital is a large-scale comprehensive tertiary 
hospital with medical, teaching, scientific research and preventive health care. The 
comprehensive ranking of the Nanfang Hospital is stable at around 15 in the domestic 
authority list, and 15 specialties have entered the top ten rankings of China's best 
specialists list (Fudan Edition).  
The liver disease center in Nanfang Hospital is the “State Key Laboratory of Organ Failure 
Research” and the “Guangdong Provincial Key Laboratory of Viral Hepatitis Research” 
and the member of the Chinese Medical Association Infectious Diseases. The center 
consists of two parts: the clinical department for patients with various liver diseases and 
the laboratory for basic research on liver diseases. In the past ten years, the research 
group has been focusing on the genomic variation and molecular mechanism of liver 
cancer development, and has achieved a series of research results. They published many 
articles in the leading journals in the field of genetics and liver diseases, like Nature 
Genetics and Hepatology. During these studies they have accumulated abundant 
experience in liver disease research and collected a large number of samples. They have 
a high-quality sample library of up to 3,000 liver cancer samples and more than 4,000 
chronic hepatitis B control samples closely matched with liver cancer cases, including the 
Qidong area in Jiangsu Province, covering many high-risk areas of the country. In 
summary, Nanfang Hospital is an outstanding teaching hospital and great place for me 
completing my capstone project. 
Hepatitis B is a liver infection disease caused by hepatitis B virus (HBV) and spreads via 
blood or body fluids among people (CDC, 2018a). HBV infection can result in various 
outcomes, from a short-term illness (Acute hepatitis B) to a lifelong infection (Chronic 
hepatitis B) (CDC, 2018b). The risk of developing a chronic hepatitis B infection depends 
on the age of who first exposure to HBV. Approximately 90% of infants who infected with 
HBV will develop a chronic hepatitis B (CHB). CHB can cause serious health issues, like 
cirrhosis, liver cancer or even death (CDC, 2018b). Globally, hepatitis B resulted in 
887,000 deaths due to complications, including cirrhosis and hepatocellular carcinoma, 
in 2015 (WHO, 2018). An estimated 257 million people are living with chronic hepatitis B 
virus infection worldwide, of which around 90 million reside China (WHO, 2016). With 
over one third of the HBV infected population of the world, China has been identified as 
the area with highest hepatitis burden (WHO, 2016). Although CHB has been found that 
was associated with approximately 90% of neonatal HBV infection and 30% of childhood 
infection (Yan et al., 2014). The mechanisms of HBV infection and CHB development still 
remains largely unknown. With rapid advances in genome-wide association studies 
(GWAS), genetic variations have received more attention and the identification of 
disease-related genetic variations has improved our understanding in the pathway of 
disease development and provided tons of potential targets for the therapeutic treatment.  
Host genetic susceptibility has also been demonstrated as an important factor which 
determines the outcome of HBV infection, such as single nucleotide polymorphism (SNPs) 
and gene copy number variations (CNVs) (He et al., 2006; Li et al., 2017a; Qiu et al., 
2017), but is not well documented.  
SNP, the most common type of genetic variation among people, is a variation in a single 
nucleotide that occurs within a gene or in a regulatory region near a gene (NIH, 2018). 
As most popular class of genetic variation among people, SNPs were demonstrated affect 
disease progression of HBV infection in many studies (Chang et al., 2014; Komatsu et al., 
2014; Li et al., 2017b; Tai et al., 2017). CNVs, another important type of genetic variation, 
received more attention recently. CNVs range from 1 Kbp to several Mbp, are defined as 
deletions or duplications of genome segments. Recently, CNVs were believed to be the 
causes of many human diseases and were associated with the susceptibility of various 
liver diseases, including HCV infection and Hepatocellular carcinoma  (Budzko et al., 
2016; Zhou et al., 2017). To date, the association of CNV with chronic Hepatitis B infection 
are still not systematically documented. 
To identify the CNVs associated with susceptibility to chronic HBV infection and outcomes, 
we recruited 2,689 CHB patients and 1,200 healthy controls from Qidong Liver Cancer 
Institute in Qidong County, China. By using the computational tool PennCNV and 
ParseCNV, we analyzed the genotyping data generated by Illumina Human OmniExpress 
BeadChip and OmniZhonghua BeadChip and evaluated the association of SNPs and 
CNVs with CHB susceptibility. We identified novel CHB associated CNVs in genes, which 
advanced the understanding of genetic factors influencing HBV infection and outcome 
and provided the potential targets related with HBV infection which have potential 




The 2,689 CHB patients and 1,200 healthy controls used in the initial GWAS scan were 
recruited by Qidong Liver Cancer Institute in Qidong County, Jiangsu Province in eastern 
China, during the period from May 2006 to December 2012. CHB patients were positive 
for both hepatitis B surface antigen (HBsAg) and antibody immunoglobulin G to hepatitis 
B core antigen for at least 6 months. The controls were collected during the same period 
time as the CHB cases were enrolled. They were randomly selected from a pool of healthy 
volunteers who visited the Qidong Liver Cancer Institute for their routinely scheduled 
physical examinations. Both the cases and controls were residents in Qidong County, 
which is one of the highest endemic regions for chronic hepatitis B virus (HBV) infection 
and HBV-related hepatocellular carcinoma (HCC) in China. For each subject, 3 ml whole 
blood was obtained for extraction of genomic DNA and 3 ml serum sample was obtained 
for detection of HBsAg and antibodies to hepatitis C virus (HCV), and human 
immunodeficiency virus (HIV) using an enzyme linked immunosorbent assay (ELISA). 
The characteristic information for each subject, including age, gender, ethnicity, HBV 
infection status and history of other liver diseases were also collected with a standard 
interviewer-administered questionnaire and/or from medical records. The exclusion 
criteria for the cases were 1) positive for antibodies to HCV, or HIV, 2) with a history of 
any other types of liver disease, such as autoimmune hepatitis, toxic hepatitis, and 
primary biliary cirrhosis, 3) not residents in Qidong County. The exclusion criteria for the 
controls, in addition to the three items of exclusion criteria for the cases, were 1) positive 
for HBsAg, 2) with a history of HBV vaccination, 3) with a history of CHB, 4) with a history 
of HCC, 5) less than 30 years old.  
 
Genotyping and quality control in GWAS 
The genome-wide genotyping analysis was conducted using Illumina Human 
OmniExpress BeadChip (delivering superior power for GWAS, providing high sample 
throughput with comprehensive genomic content and including 733,202 single-nucleotide 
polymorphisms [SNPs] across the genome) for cases and OmniZhonghua BeadChip 
(delivering exceptional coverage of common, intermediate, and rare variation found within 
Chinese populations for GWAS and including 900,015 SNPs, containing ~80% of the 
SNPs in HumanOmniExpress BeadChip) for controls at Genergy Biotechology Inc. 
(Shanghai, China). Genotyping was performed according to the Infinium HD protocol from 
Illumina (San Diego, CA).   
During individual quality control of genotyping data, samples were removed if they (i) had 
an overall genotyping rate of <95%; or (ii) were duplicates or showed familial relationships 
(PI_HAT > 0.025). SNPs will be excluded if they had (i) a call rate of <95%; (ii) a minor 
allele frequency (MAF) of <0.01; or (iii) P < 1 × 10−3 in a Hardy-Weinberg equilibrium test 
among controls.  
During individual quality control analysis of CNV calling, samples with highly variable 
signal intensity were removed, including (i) LRR_SD(standard deviation of Log R 
Ratio) >0.3; (ii) BAF_drift (measuring departure of the B Allele Frequency from the 
expected values) > 0.01; (iii) WF(waviness factor, the amount of dispersion in signal 
intensity) >0.05 or WF<-0.05; (iv) Number of CNVs>50 (number of called-CNVs).  
 
CNV calling 
CNV Calling Raw signal intensity files were first generated by the export function provided 
in Illumina GenomeStudio. Then we used UCSC Genome Browser’s liftover tool to map 
SNPs to the newer reference genome assembly (http://genome.ucsc.edu /cgi-
bin/hgLiftOver). PennCNV is a software tool for Copy Number Variation (CNV) detection 
from SNP genotyping arrays. By removing probes that can not be uniquely mapped to the 
genome and choosing proper population frequency of B allele (PFB) and GCmodel files, 
we used PennCNV to identify CNVs and generated a quality control summary for each 
sample (Lin CF et al., 2013).  
 
Quality Controls in CNV calling 
During CNV calling, CNVs were removed if (i) number of SNPs spanning less than 10; (ii) 
length of CNV <50 kb. We also removed the CNVs calls located in certain regions, 
including HLA regions, immunoglobulin regions, telomere regions, centromere regions. 
Previous studies show that these regions were especially likely to harbor spurious CNV 
calls(Wang et al., 2007). 
 
 
Statistical Analysis  
Predicted CNVs from the sample genomic locus can have various start and end points 
across individuals. To make the analysis simpler, we divided the genome into copy 
number polymorphic regions (CNPRs). Each individual was then assigned a copy number 
(CN) state for each CNPR according to the CNV predicted in that region, with CN = 2 if 
no CNV was predicted. In order to distinguish the CNV with a single duplication of one 
allele and single deletion of the other (CN=2) from non-CNV status (CN=2), we further 
encoded CN state with deletion and duplication variables. Plink 1.09 was used to perform 
association analysis (Purcell S et al., 2007). The outcome variable was a binary variable 
indicating HBV infection.  Explanatory variables were age, gender, and CNV type. Logistic 
regression analysis was used to adjust for age, gender as well as CNV type. Fisher exact 
tests were used if 25% of cells with expected count were less than 5. If all expected counts 
were greater or equal to 5, Chi-squared tests were used to compare categorical variables. 




The characteristics of the recruited patients were summarized in Table 1. There were 
2,689 CHB patients (69.14%) and 1,200 healthy controls (30.86%). However, 70 healthy 
controls and 181 CHB patients were found missing the age and gender information and 
were excluded for analysis. The total number of healthy controls used in the analysis was 
1,130, while the number of CHB patients was 2,508. The median age for normal people 
was 52 years (range, 30-80 years), the median age for CHB patients was 50 years (range, 
15-87 years). There were 722 males (63.89%) and 408 females (36.11%) among the 
healthy controls, while 1,818 males (72.49%) and 690 females (27.51%) among the CHB 
patients.  















Group Variable No. (%) 
Control 
(n=1,200) 
Median age, years (range) 52 (30 to 80) 
Male 722 (63.89) 
Female 408 (36.11) 
Missing 70 (5.83) 
Final Num 1,130 
CHB patients 
(n=2,689) 
Median age, years (range) 50 (15 to 87) 
Male 1,818 (72.49) 
Female 690 (27.51) 
Missing 181 (6.73) 
Final Num 2,508 
 
 
The distributions of age and gender of controls and CHB patients were shown in the 
Figure. 1. 
 
Figure 1. Age and Gender distribution of normal controls and CHB patients. (A) The 
boxplot of age distribution of normal controls and CHB patients. (Blue- normal controls; 
Red- CHB patients).  (B) Gender distribution of normal controls and CHB patients. 
(Blue- male; Red- female). 
 
SNP-based CNV Analysis 
We implemented the case-control association analysis following the PennCNV 
introduction (PennCNV) which were used to identify the stretch of SNPs that tend to have 
copy number changes in CHB cases versus controls by Fisher’s Exact Test. The P-values 
derived from the Fisher Exact Test comparing CHB cases and controls, were generally 
shown by Manhattan plot. The Manhattan plot was produced by scattering the P-values 
in -log10 scale in the vertical axis and the physical position of SNP along chromosomes 
in the horizontal axis. Different chromosomes were generally distinguished with colors. 
Using -log10 scale was to highlight the small P-values, which suggested potential 
disease-related SNPs (Zeng et al., 2015). The horizontal solid red line marked a 
significance cut off of 10-8, and the horizontal dashed blue line marked a significance cut 
off of 10-6. As shown in figure 2, the Manhattan plot displayed the -log10 deviance P value 
for CNV losses in the SNP-based CNV test. We identified 110 loci (p<10-8) with deletion 
enrichment in the CHB cases. While the Figure. 3 displayed the -log10 deviance P value 
for CNV gains in the SNP-based CNV test. There were 124 loci (p<10-8) with duplication 
enrichment in the CHB cases were found here.  
 
Figure 2. SNP-based CNV Manhattan plot. Manhattan plot displayed the -log10 deviance 
P value for CNV losses in the SNP-based CNV test. The y-axis showed the distribution 
of –log10 (p) where p was the Fisher’s Exact Test P-value for copy number changes in 
CHB cases versus controls. P value cutoffs corresponding to10-6 and 10-8 were 
highlighted in red solid line and blue dashed line, respectively. The x-axis showed 
chromosomes numbered from 1 (left) to X (right). 
 
Figure 3. SNP-based CNV Manhattan plot. Manhattan plot displayed the -log10 deviance 
P value for CNV gains in the SNP-based test. The y-axis showed the distribution of –log10 
(p) where p was the Fisher’s Exact Test P-value for copy number changes in CHB cases 
versus controls. P value cutoffs corresponding to10-6 and 10-8 were highlighted in red 
solid line and blue dashed line, respectively. The x-axis showed chromosomes numbered 
from 1 (left) to X (right). 
 
CNPR-based CNV Analysis 
To further identify the specific loci that confer risk of HBV infection, we preformed the 
CNPR-based CNV analysis and found 8 deletion CNPRs, as well as 3 duplication CNPRs 
were significantly changed between CHB patients and healthy controls. Moreover, there 
were nine genes revealed the copy number loss, including FGFR3 (p=1.49X10-7), FGR-
3 (p=1.49X10-7), LETM1 (p=1.49X10-7), TACC3 (p=1.49X10-7), TMEM129 (p=1.49X10-7), 
PANK4 (p=4.55X10-4), PLCH2 (p=4.55X10-4), CED-6 (p=2.04X10-4), DIRC1 (p=2.04X10-
4), as well as three genes revealed the copy number gain, including FLJ43080 
(p=2.50X10-5), CSMD3 (p=6.288X10-5), MGAT4C (p=1.52X10-4) in CHB patients 
compared with healthy controls. Besides the CNPRs in genes, the intergenic regions 
chr19:32757923-32761177 (p=8.97X10-54), chr11:50432844-50586426 (p=7.76X10-12), 
chr9:12003711-12010873 (p=5.79X10-8), chr19:24244157-24354405 (p=4.55X10-4), 
chr5:18673077-18728095 (p=9.02X10-38) were also associated with CHB. Among these 
genes, the function of FGFR3 and CSMD3 have been demonstrated by other researchers 
related with the HBV infection (Lai et al., 2016; Van et al., 2016); while, the other genes 





Table 2. Gene-based CNV Analysis 
CNPR* N in Cases N in Control Nearby Gene 
Distance from 
Nearby Gene, bp P** 
Deletion           
chr19:32757923-32761177 243 0 AK075337 60054 8.97E-54 
chr11:50432844-50586426 52 0 AB231715, AB231716, AB231717 96465 7.76E-12 
chr9:12003711-12010873 77 11 TYRP1 672513 5.79E-08 
chr4:1690555-1785787 32 0 
FGFR3, FGR-3, LETM1, TACC3, 
TMEM129 0 1.49E-07 
chr1:2369108-2444569 16 0 PANK4, PLCH2 0 4.55E-04 
chr19:24244157-24354405 16 0 LOC100101266 106068 4.55E-04 
chr5:18673077-18728095 1 94 BC028204 706723 9.02E-38 
chr2:189165214-189310804 2 13 CED-6, DIRC1 0 2.04E-04 
Duplication           
chr5:109856282-109991005 22 0 FLJ43080 0 2.50E-05 
chr8:114024371-114181033 36 4 CSMD3 0 6.288E-05 
chr12:85169592-85337570 19 0 MGAT4C 0 1.52E-04 
*CNPR, copy number polymorphic region (hg18)         
**Fisher exact test was used and used 5x10-4 as the significant cutoff. 5x10-4 is a conservative bar for CNV genome-wide significance surviving 
multiple testing correction based on analysis of Illumina and Affymetrix genome-wide SNP arrays. 
Red highlight: Genes have been linked with HBV previously 
Discussion 
Accounting for one third of chronic hepatitis B virus infection occurrence in the world, the 
chronic hepatitis B infection and HBV-related complications has become large disease 
burden in China. There are more than 90 million chronic carriers of HBV in China and 
most people with HBV infection in China are unaware that they carry the disease (Chen, 
2018). HBV is a member of small DNA viruses and infects one major cell of liver, 
hepatocytes. Using a RNA proviral intermediate, HBV replicates by reverse transcription 
(Beck and Nassal, 2007). It is known that HBV infection can result in various clinical 
conditions and approximately 90% of neonatal HBV infection and 30% of childhood 
infection will finally develop to CHB (Yan et al., 2014). The main risk factors related with 
CHB include familial spread, infant infection, infection due to immunologic inadequacy, 
and a history of other liver disease (Qiu et al., 2017). The causes of the CHB are intricated 
and remain largely unknown.  
It has been demonstrated that host genetic susceptibility is an important factor which 
determines the outcome of HBV infection(He et al., 2006; Li et al., 2017a; Qiu et al., 2017). 
In 2013, Chiao-Feng et al proposed a method which make us possible to call CNVs 
directly from the GWAS genotyping data (Lin et al., 2013). And recently, by using this 
method, some CNVs were firstly identified to be associated with schizophrenia and 
hepatocellular carcinoma (Purcell et al., 2007; Sakai et al., 2015; Zhou et al., 2017). But 
CHB related CNVs are rarely reported. In the current study, we analyzed the genotyping 
data generated from CHB patients and normal controls and found 8 deletion CNPRs, as 
well as 3 duplication CNPRs are significantly changed between CHB patients and healthy 
controls. Moreover, there were nine genes revealed the copy number loss, including 
FGFR3 (p=1.49X10-7), FGR-3 (p=1.49X10-7), LETM1 (p=1.49X10-7), TACC3 (p=1.49X10-
7), TMEM129 (p=1.49X10-7), PANK4 (p=4.55X10-4), PLCH2 (p=4.55X10-4), CED-6 
(p=2.04X10-4), DIRC1 (p=2.04X10-4), as well as three genes revealed the copy number 
gain, including FLJ43080 (p=2.50X10-5), CSMD3 (p=6.288X10-5), MGAT4C (p=1.52X10-
4) in CHB patients compared with healthy controls. Besides the CNPRs in genes, the 
intergenic regions chr19:32757923-32761177 (p=8.97X10-54), chr11:50432844-
50586426 (p=7.76X10-12), chr9:12003711-12010873 (p=5.79X10-8), chr19:24244157-
24354405 (p=4.55X10-4), chr5:18673077-18728095 (p=9.02X10-38) were also associated 
with CHB. Among these genes, the function of FGFR3, LETM1, CED-6 and CSMD3 have 
been demonstrated by other researchers related with the HBV infection. Although other 
genes’ functions in the HBV infection and CHB development haven’t been demonstrated, 
they could be the potential targets for CHB prevention and therapy.  
Interestingly, FGFR3, a protein coding gens, makes a protein called Fibroblast Growth 
Factor Receptor 3. The FGFR3 protein plays important role in cellular processes, 
including regulation of cell growth and proliferation, determination of cell type, 
angiogenesis, wound healing and so on. Related studies found over-expressed FGFR3 
levels in human hepatocellular carcinoma (Qiu et al., 2005). Moreover, FGFR3 has been 
well documented in the various cancer and suggested as therapeutic target, including 
bladder cancer (Gust et al., 2013),   lung cancer (Yin et al., 2016) and urothelial carcinoma 
(Kim et al., 2018). In this study, we found significant deletion of copy number in FGFR3 
in CHB cases compared with healthy controls which indicated the important role of 
FGFR3 in CHB disease progress and could be a potential risk factor for the hepatocellular 
carcinoma development.  
CSMD3 (CUB and Sushi multiple domains 3) is a gene encodes a protein and functions 
as a tumor suppressor. Lai et.al created a transgenic mouse models by transferring the 
HBV pre-S/S gene and its promoter into C57B6 mice and found decreased CSMD3 
expression in the mice models which indicated that downregulation of CSMD3 may 
contribute to the hepatocarcinogenesis. We found significant duplication of copy number 
in CSMD3 in CHB cases compared with healthy controls which confirmed the role of 
CSMD3 in HBV related hepatocarcinogenesis. 
Although, there were 8 genes revealed copy number deletion and 2 genes revealed copy 
number duplications that were not linked with HBV infection or CHB previously. Our 
findings also provided rational targets for the disease prevention. For example, LETM1 
(Leucine Zipper And EF-Hand Containing Transmembrane Protein 1), involved in the 
transport of charged calcium atoms (calcium ions) across membranes within mitochondria, 
was found been upregulated in the breast cancer (Li et al., 2015) Besides the LETM1, 
FGR, DIRC1, TACC3 and MGAT4C were also found related with various type of cancer. 
For example, FGR was over-expressed in the primary tumor samples (Stransky et al., 
2014); overexpression of DIRC1 was associated with tumor progression in gastric 
cancer(Li et al., 2018); TACC3 was found involved in proliferation and differentiation of 
tumor cells, cancer progression and metastasis (Zhao et al., 2018). Moreover, TMEM129 
were found related with the virus infection. TMEM129, as a novel E3 ligase, is hijacked 
by the human cytomegalovirus and play role in averting immune recognition of the 
infected cell (van den Boomen et al., 2014). Our results manifested these genes might be 
potential targets of HBV infection and related disease. The impact of copy number 
variations on gene expression complex and haven’t been fully elucidated. But the CHB-
related CNVs identified by us could be potential targets. The further confirmation and 
identification of these genes are needed which help elucidate underlying mechanisms of 
HBV infection and CHB progression.  
There are also several limitations of our study. Firstly, we do not have access to 
information about the medical information, education, risk behaviors of subjects in the 
clinical cohort. It is possible that these risk factors affect our results and the associations 
we saw in our study are due to population stratification. Secondly, our population-based 
study was performed exclusively in Chinese individuals and thus might not be 
generalizable to other ancestries. Thirdly, our findings in this study may need further 
validation by using other independent samples.  
 
Conclusions 
We analyzed the genotyping data generated from CHB patients and normal controls and 
identified 110 loci (p<10-8) with deletion enrichment and 124 loci (p<10-8) with duplication 
enrichment in the CHB cases. We also found nine genes revealed the copy number loss, 
including FGFR3 (p=1.49X10-7), FGR-3 (p=1.49X10-7), LETM1 (p=1.49X10-7), TACC3 
(p=1.49X10-7), TMEM129 (p=1.49X10-7), PANK4 (p=4.55X10-4), PLCH2 (p=4.55X10-4), 
CED-6 (p=2.04X10-4), DIRC1 (p=2.04X10-4), as well as three genes revealed the copy 
number gain, including FLJ43080 (p=2.50X10-5), CSMD3 (p=6.288X10-5), MGAT4C 
(p=1.52X10-4) in CHB patients compared with healthy controls, which providing novel 





Informed consent was obtained from all subjects before their participation in the study. 
The study was approved by the ethics committee of Qidong Liver Cancer Instituteand 
conducted in accord with the Declaration of Helsinki principles. 
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Capstone Experience Reflection 
My experience with the placement site 
It’s my great honor to work in the Southern Medical University Nanfang Hospital and thank 
my preceptor gave me this opportunity to work with him. I believe what I learnt during this 
period will benefit me a lot in my future works. 
As mentioned previously, chronic hepatitis B virus infection is a serious disease burden 
and public health issue in China. I am very interested in CHB related research and public 
health activities. Nanfang Hospital is a large-scale comprehensive tertiary hospital with 
medical, teaching, scientific research and preventive health care. They did a lot of efforts 
on the HBV infection prevention and therapy. As I have known, the Nanfang hospital 
provides three years’ free therapy to the HBV patients and arranges HBV prevention-
related activities every year. They also give strong support to the HBV-related researches 
and made outstanding contributions in understanding the mechanisms of HBV infection 
and CHB progression.  
I started the work of identifying the CHB associated CNVs from genotyping data with my 
preceptor on August, 2018 and it has been half year. During this period, I learnt the 
genome-wide association study (GWAS) for my first time. GWAS studies are very 
complex for me and I have no idea about its principle, application and method at the 
beginning. After the learning during this period, I realized that GWAS, an observational 
study of a genome-wide set of genetic variants in different individuals, is very powerful 
and useful tool in detecting common genetic variants associated with complex disorders. 
The study design and statistical method for GWAS are very interesting for me. Although 
I didn’t have chance to be involved in the data collection process (i.e., recruiting 
participants, collecting samples, and generating data), I still went over thousands of 
human data, which was not expected by me. It’s my first time to handle such a large size 
of data. Moreover, I can’t physically work in the Nanfang hospital as my full-time work in 
the United States, the distance and jet lag were all the difficult part for moving this project. 
I very appreciate the help from my preceptor who work in the late night to help me 
understand this project and solve the problems. I also learnt new software this period 
which I find is very useful, including Xshell and PennCNV. Xshell is a powerful terminal 
emulator from South Korea, supports SSH1, SSH2, FTP, SFTP, Telnet, rlogin, and Serial 
protocols. It enables users to directly connect to the remote hosting via Internet, so as to 
easily control Linux servers on Windows. By using the Xshell, I can access the data in 
Nanfang Hospital using my laptop and work on the analysis easily. PennCNV is an 
excellent tool for Copy Number Variation (CNV) detection from SNP genotyping arrays. It 
can be used to identify a stretch of SNPs that tend to have copy number changes in cases 
versus controls using Fisher’s Exact Test. By using these two softwares, we found 
interesting CNVs associated with the susceptibility of CHB. 
 
Greatest contributions/accomplishments 
The greatest accomplishments I made from my capstone project are helping in the data 
cleaning, SNP-based CNV analysis, gene-based CNV analysis and give suggestions in 
the statistical method. We analyzed the genotyping data generated from CHB patients 
and normal controls and identified 110 loci (p<10-8) with deletion enrichment and 124 loci 
(p<10-8) with duplication enrichment in the CHB cases. We also found nine genes 
revealed the copy number loss, including FGFR3 (p=1.49X10-7), FGR-3 (p=1.49X10-7), 
LETM1 (p=1.49X10-7), TACC3 (p=1.49X10-7), TMEM129 (p=1.49X10-7), PANK4 
(p=4.55X10-4), PLCH2 (p=4.55X10-4), CED-6 (p=2.04X10-4), DIRC1 (p=2.04X10-4), as 
well as three genes revealed the copy number gain, including FLJ43080 (p=2.50X10-5), 
CSMD3 (p=6.288X10-5), MGAT4C (p=1.52X10-4) in CHB patients compared with healthy 
controls, which providing novel diagnosis markers and targets in HBV infection and CHB 
progression, which providing novel diagnosis markers and targets in HBV infection and 
CHB progression. 
I also worked on the Patient characteristics. We previously had 2,689 CHB patients and 
1,200 healthy controls. We didn’t perform the all the patient’s data for this study, because 
some of patients’ information was missing. I worked on clean the data to narrow the 
population in this study to 2,508 CHB patients and 1,130 healthy controls. 
As I have the pharmacology background previously, I contributed in validating the 
pharmacology functions of associated genes identified from our analysis. The GWAS data 
is useless if we don’t know the identified genes’ biology functions. My participation helped 
make the findings more meaningful. 
 
Greatest challenges 
The greatest challenges we met is the distance and jet leg during our communication 
and work. I couldn’t physically work in Nanfang hospital which do bring inconvenience 
during this period. At the beginning, we couldn’t find proper time zone for the discussion 
and I have the difficult to access the database in Nanfang hospital. In the other hand, 
the GWAS is a brand new field for me. I need spend lots of time on reading literatures to 
help me understand the purpose, principle, methods in this study. I worried a lot at the 
beginning as the project didn’t move smoothly. I appreciate the tolerance and patience 
from my preceptor. My preceptor gave me lots of encourage and helped me on every 
small issue I met. We communicated every week and found best time work for both of 
us. With the help from my preceptor, I learnt to use the Xshell and finally accessed the 
data base in Nanfang hospital successfully. Although I had a hard time at the beginning, 
the long-distance work experiences make me stronger and push me learn more skills, 
including time planning, communications, terminal emulator tools and so on.  
 
Views of public health practice 
Public health practice can’t ignore the impact of genomics in the 21st century. I didn’t 
realize the importance of genomics for public health practice before. After my capstone 
project, I have understand better how the genomics impact the public health practice. 
With the rapid advance of genomics technologies, predication of individual risks by 
genomics studies could affect clinical therapy strategies. Developments in public health 
practice will be necessary to ensure rapid and effective implementation of genomics 
studies. 
 
Public health education 
My public health education help me understand better the ethical issues in the GWAS. 
GWAS data is derived from DNA information which is a powerful personal identifier and 
provide information not just on the individual, but also on the individual’s relatives, related 
groups, and population. The GWAS data contains large amount of individual-specific 
digital information and can be easily share across the internet. To understand better the 
ethical issues in GWAS, I read lots of literatures and found there are three important 
aspects of the context of genome research methods that may affect the ethical challenges, 
including one data using in many different projects; data sharing; unauthorized use of 
digital information. In our study, we don’t have access of patients’ medical history, family 
information, personal information. So all of these factors are not used in the analysis.  
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